Safety and efficacy of cyclooxygenase-2 inhibition for treatment of primary hypertrophic osteoarthropathy: A single-arm intervention trial.
COX, Cyclooxygenase
COX-2 inhibitor
HPGD, hydroxyprostaglandin dehydrogenase
PGE2, prostaglandin E2
PHO, Primary hypertrophic osteoarthropathy
Primary hypertrophic osteoarthropathy
Prostaglandin
SLCO2A1, solute carrier organic anion transporter family, member 2A1
Treatment
Journal
Journal of orthopaedic translation
ISSN: 2214-031X
Titre abrégé: J Orthop Translat
Pays: Singapore
ID NLM: 101625127
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
28
06
2018
revised:
27
09
2018
accepted:
02
10
2018
entrez:
12
9
2019
pubmed:
12
9
2019
medline:
12
9
2019
Statut:
epublish
Résumé
Primary hypertrophic osteoarthropathy (PHO) is a rare disease involving joint, bone and skin. Two underlying genes responsible for this disease-hydroxyprostaglandin dehydrogenase ( We recruited patients presenting to Peking Union Medical Hospital between January 2009 and December 2016 who were diagnosed with PHO. Participants were given the COX-2 inhibitor etoricoxib (60 mg once daily) and followed up for 9 months. Gene analysis was performed at baseline. The following data were collected at baseline and during treatment: visual analogue score (VAS), volume of the distal middle finger (VDMF), knee joint circumference (KJC), serum and urinary levels of prostaglandin E2 (PGE2) and PGE metabolite (PGE-M) and serum levels of inflammatory markers. A total of 27 patients were recruited, including seven patients with PHO type I (PHOAR1) carrying We found COX-2 inhibitor to be safe and effective for the treatment of PHO in our cohort. The underlying genes responsible for PHO suggest COX inhibitor as potential therapy, and our study demonstrates the efficacy and safety of this treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Primary hypertrophic osteoarthropathy (PHO) is a rare disease involving joint, bone and skin. Two underlying genes responsible for this disease-hydroxyprostaglandin dehydrogenase (
METHODS
METHODS
We recruited patients presenting to Peking Union Medical Hospital between January 2009 and December 2016 who were diagnosed with PHO. Participants were given the COX-2 inhibitor etoricoxib (60 mg once daily) and followed up for 9 months. Gene analysis was performed at baseline. The following data were collected at baseline and during treatment: visual analogue score (VAS), volume of the distal middle finger (VDMF), knee joint circumference (KJC), serum and urinary levels of prostaglandin E2 (PGE2) and PGE metabolite (PGE-M) and serum levels of inflammatory markers.
RESULTS
RESULTS
A total of 27 patients were recruited, including seven patients with PHO type I (PHOAR1) carrying
CONCLUSIONS
CONCLUSIONS
We found COX-2 inhibitor to be safe and effective for the treatment of PHO in our cohort.
THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE
UNASSIGNED
The underlying genes responsible for PHO suggest COX inhibitor as potential therapy, and our study demonstrates the efficacy and safety of this treatment.
Identifiants
pubmed: 31508314
doi: 10.1016/j.jot.2018.10.001
pii: S2214-031X(18)30101-3
pmc: PMC6718875
doi:
Types de publication
Journal Article
Langues
eng
Pagination
109-118Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Références
J Pharmacol Exp Ther. 2001 Feb;296(2):558-66
pubmed: 11160644
Clin Rheumatol. 2007 Jan;26(1):8-11
pubmed: 16738844
Nat Clin Pract Rheumatol. 2006 Aug;2(8):452-6; quiz following 456
pubmed: 16932737
J Assoc Physicians India. 2006 Apr;54:340
pubmed: 16944626
Nat Genet. 2008 Jun;40(6):789-93
pubmed: 18500342
Clin Rheumatol. 2009 Oct;28(10):1229-33
pubmed: 19455364
Medicine (Baltimore). 1991 May;70(3):208-14
pubmed: 2030644
J Am Acad Dermatol. 2010 Dec;63(6):1036-41
pubmed: 20933299
Bioorg Med Chem Lett. 2011 Oct 15;21(20):6071-3
pubmed: 21903394
Am J Hum Genet. 2012 Jan 13;90(1):125-32
pubmed: 22197487
Hum Mutat. 2012 Apr;33(4):660-4
pubmed: 22331663
Rheumatology (Oxford). 2012 Dec;51(12):2234-8
pubmed: 22923763
J Clin Endocrinol Metab. 2013 May;98(5):E923-33
pubmed: 23509104
Reumatismo. 2013 May 27;65(2):82-5
pubmed: 23877413
Mod Rheumatol. 2015 Mar;25(2):315-21
pubmed: 24533558
Cancer Prev Res (Phila). 2014 Aug;7(8):805-12
pubmed: 24838973
Physiol Rev. 2015 Jan;95(1):83-123
pubmed: 25540139
Biomed Res Int. 2015;2015:595273
pubmed: 26000299
J Bone Miner Res. 2017 Aug;32(8):1659-1666
pubmed: 28425581
Bone. 2018 Jan;106:96-102
pubmed: 28963081
J Clin Rheumatol. 2018 Apr;24(3):164-167
pubmed: 29239930
J Dermatol Sci. 2018 Apr;90(1):21-26
pubmed: 29305259
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2018 Apr 10;35(2):156-159
pubmed: 29652982
Indian J Dermatol Venereol Leprol. 2018 Jul-Aug;84(4):446-447
pubmed: 29770782